Last updated on September 2017

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Brief description of study

This a randomized controlled Phase 2/3 study to evaluate the efficacy and safety of SHR-1210 in subjects with advanced HCC who failed or intolerable to prior systemic treatment. The primary study hypothesis is that SHR-1210 treatment improves Objective Response Rate and Overall Survival when compare with SOC.

Detailed Study Description

In June 2017, this study was revised to expand the Phase 2 part to enroll more subjects and remove the Phase 3 part under the same protocol. A Phase 3 study will be initiated separately.

Clinical Study Identifier: NCT02989922

Find a site near you

Start Over

81 Hospital Nanjing

Nanjing, China
  Connect »